PRESENT
Our study combined data from six different institutions across the United States and Europe, of patients diagnosed with hepatocellular carcinoma, cholangiocarcinoma, or gallbladder cancer between 2006 and 2016 who then underwent robotic liver resections . 5 We showed that overall survival and disease-free survival of patients undergoing robotic liver surgery is comparable to the published data on laparoscopic liver surgery. Seeing that these outcomes are comparable allows for increased interest in utilization of the robotic platform. Due to the limitations associated with laparoscopy, including decreased range of motion, limited two-dimensional view, and poor ergonomics, robotic liver surgery gained popularity. 3 The downside to the robotic platform that still exists is the large learning curve associated with robotic surgery. As most current liver surgeons gained exposure to the robotic platform years after residency training, robotic surgery for liver resections is, in general, associated with longer operating room times as well as larger financial burden due to the cost of initial purchase and maintenance.
FUTURE
With the increase in utilization of robotic surgery throughout a variety of surgical specialties, more surgeons are incorporating the use of the robotic platform early in their careers, and, most importantly, more residencies are integrating robotic surgery into their core curriculum. Similar to the transition from open to laparoscopic surgery, the hope is for robotic surgery to become more cost efficient and to allow surgeons the ability to perform more complex procedures with superior visualization and ergonomics. Due to the unique ability of the dual-console robotic system allowing surgeons to teach the use of this new technology while continuing to have full control of the system itself allows residents to gain great exposure and practice. As the ability to perform robotic surgery continues to become a core skill, in the future we will commonly have more choices in forms of minimally invasive surgeries to provide patients with the best results.
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